Kemwell Biopharma

Bengaluru, India Founded: 1980 • Age: 46 yrs Acquired By Recipharm
Integrated biologics development and manufacturing are provided as a CDMO.

About Kemwell Biopharma

Kemwell Biopharma is a company based in Bengaluru (India) founded in 1980 by Subhash Bagaria was acquired by Recipharm in April 2016.. Kemwell Biopharma has raised $5.72 million across 2 funding rounds from investors including Recipharm, Subhash Family Trust and Karan Bagaria. The company has 296 employees as of March 18, 2025. Kemwell Biopharma has completed 1 acquisition, including Cirrus Pharmaceuticals. Kemwell Biopharma offers products and services including Biologics Development, Biologics cGMP Manufacturing, Quality Control, and Formulation Development. Kemwell Biopharma operates in a competitive market with competitors including KBI Biopharma, Aldevron, Eurogentec, Ovagen and Laurus Bio, among others.

  • Headquarter Bengaluru, India
  • Employees 296 as on 18 Mar, 2025
  • Founders Subhash Bagaria
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Kemwell Biopharma Private Limited
  • Date of Incorporation 07 May, 2008
  • Jurisdiction Bangalore, Karnataka, India
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $25.37 M (USD)
    49.72
    as on Mar 31, 2024
  • Net Profit
    $5.87 M (USD)
    690.4
    as on Mar 31, 2024
  • EBITDA
    $13.56 M (USD)
    411.32
    as on Mar 31, 2024
  • Total Equity Funding
    $5.72 M (USD)

    in 2 rounds

  • Latest Funding Round
    $4.26 M (USD), Unspecified

    Mar 26, 2015

  • Investors
    Recipharm

    & 5 more

  • Employee Count
    296

    as on Mar 18, 2025

  • Investments & Acquisitions
  • Acquired by
    Recipharm

    (Apr 18, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Kemwell Biopharma

Kemwell Biopharma offers a comprehensive portfolio of products and services, including Biologics Development, Biologics cGMP Manufacturing, Quality Control, and Formulation Development. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Focuses on process and formulation for biologics therapeutics.

Produces drug substances and products under cGMP standards.

Ensures analytical testing and quality assurance for biologics.

Develops formulations for biologics drug products.

People of Kemwell Biopharma
Headcount 1000-5000
Employee Profiles 18
Board Members and Advisors 1
Employee Profiles
People
Deivendran K
Executive
People
Sanjay Lodha
Vice President, Operations
People
Anurag Bagaria
Chairman & CEO
People
Diksha Gupta
Director Of Business Development

Unlock access to complete

Board Members and Advisors
people
Shabbir Anik
Strategic Advisor

Unlock access to complete

Funding Insights of Kemwell Biopharma

Kemwell Biopharma has successfully raised a total of $5.72M across 2 strategic funding rounds. The most recent funding activity was a Unspecified round of $4.26 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Unspecified — $4.3M
  • First Round

    (27 Mar 2014)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2015 Amount Unspecified - Kemwell Biopharma Valuation Kum Kum Bagaria
Mar, 2014 Amount Unspecified - Kemwell Biopharma Valuation Kum Kum Bagaria
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Kemwell Biopharma

Kemwell Biopharma has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include Recipharm, Subhash Family Trust and Karan Bagaria. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Angel
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Pharmaceutical development and manufacturing services are offered contractually.
Founded Year Domain Location

Karan Bagaria

Founder of KemTree, angel investor in health and wellness startups
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Kemwell Biopharma

Kemwell Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cirrus Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Development services for inhaled, oral, topical, transdermal and parenteral products
1997
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Kemwell Biopharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Kemwell Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Kemwell Biopharma

Kemwell Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, Aldevron, Eurogentec, Ovagen and Laurus Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of protein formulation, process & cell line development, and cGMP services
domain founded_year HQ Location
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
domain founded_year HQ Location
Oligonucleotides, peptides, and antibodies are developed and manufactured by Eurogentec.
domain founded_year HQ Location
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
domain founded_year HQ Location
Precision fermentation services for biopharma and food are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Kemwell Biopharma

Frequently Asked Questions about Kemwell Biopharma

When was Kemwell Biopharma founded?

Kemwell Biopharma was founded in 1980 and raised its 1st funding round 34 years after it was founded.

Where is Kemwell Biopharma located?

Kemwell Biopharma is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Who is the current CEO of Kemwell Biopharma?

Anurag Bagaria is the current CEO of Kemwell Biopharma.

Is Kemwell Biopharma a funded company?

Kemwell Biopharma is a funded company, having raised a total of $5.72M across 2 funding rounds to date. The company's 1st funding round was a Unspecified of $1.46M, raised on Mar 27, 2014.

How many employees does Kemwell Biopharma have?

As of Mar 18, 2025, the latest employee count at Kemwell Biopharma is 296.

What is the annual revenue of Kemwell Biopharma?

Annual revenue of Kemwell Biopharma is $25.37M as on Mar 31, 2024.

What does Kemwell Biopharma do?

Kemwell Biopharma was founded in 1980 and is based in Bengaluru, India. Operations focus on the biologics sector, where integrated contract development and manufacturing organization (CDMO) services are delivered. Drug substance and drug product manufacturing are handled, alongside process and analytical development. Support extends to monoclonal antibodies, fusion proteins, and other mammalian cell-culture-based protein therapeutics. Quality control and assurance are maintained in compliance with cGMP standards.

Who are the top competitors of Kemwell Biopharma?

Kemwell Biopharma's top competitors include KBI Biopharma, Aldevron and Ovagen.

What products or services does Kemwell Biopharma offer?

Kemwell Biopharma offers Biologics Development, Biologics cGMP Manufacturing, Quality Control, and Formulation Development.

How many acquisitions has Kemwell Biopharma made?

Kemwell Biopharma has made 1 acquisition, including Cirrus Pharmaceuticals.

Who are Kemwell Biopharma's investors?

Kemwell Biopharma has 6 investors. Key investors include Recipharm, Subhash Family Trust, Karan Bagaria, Kum Kum Bagaria, and Anurag Bagaria.

What is Kemwell Biopharma's valuation?

The valuation of Kemwell Biopharma is $12.72M as of Mar 2015.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available